IMMUNOGLOBULIN G1 (DE-450-LYSINE), ANTI-(HUMAN TYROSINE KINASE RECEPTOR AXL) (HUMAN-MUS MUSCULUS MONOCLONAL BA301 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL BA301 .KAPPA.-CHAIN, DIMER, THIOETHER WITH N-(((4-((N-(6-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-1-OXOHEXYL)-L-VALY L-N5-(AMINOCARBONYL)-L-ORNITHYL)AMINO)PHENYL)METHOXY)CARBONYL)-N-METHYL-L-VALYL-N-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1R,2S)-2-HYDROXY-1-METHYL-2-PHENYLETHYL)AMINO)-1-METHOXY-2-METHYL-3-OXOPROPYL)-1-PYRROLIDINYL)-2-METHOXY-1-((1S)-1-METHYLPROPYL)-4-OXOBUTYL)-N-METHYL-L-VALINAMIDE
Ovarian Cancer
Canadian Cancer Trials Groupantibody_drug_conjugatePhase 2Active
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 59/ 100
Competitive context
524 Active assets in the Ovarian Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tisotumab Vedotin Seagen Inc. | Phase 2 | BB |
TIL Inge Marie Svane | Phase 2 | BB |
Olaparib Shandong University | Phase 4 | BB |
Carboplatin Fudan University | Phase 4 | BB |
Irinotecan ARCAGY/ GINECO GROUP | Phase 4 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →